Company Overview: Intelli Pharmaceutics

Industry News

10 May

Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®

TORONTO, May 10, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (IPCI)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that it has today received final approval from the U.S. Food...

Read more

16 Mar

Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”

TORONTO, March 16, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that, effective at the opening of trading on Monday, March 20,...

Read more

24 Feb

Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR

TORONTO, Feb. 24, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that the Company today received final approval from the U.S. Food...

Read more

10 Feb

Intellipharmaceutics Announces 2016 Year End Results

TORONTO, Feb. 10, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30,...

Read more

3 Feb

Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for...

Read more

6 Jan

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

TORONTO, Jan. 06, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs today announced that its United States (“U.S.”) marketing partner, Par Pharmaceutical (“Par”), has...

Read more

29 Dec

Intellipharmaceutics to Present at the Biotech Showcase™

TORONTO, Dec. 29, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the annual...

Read more

21 Dec

Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose Technology

TORONTO, Dec. 21, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that U.S. Patent No. 9,522,119 and Canadian Patent No. 2,910,865 were...

Read more

29 Nov

Intellipharmaceutics to Present at the LD Micro Main Event

TORONTO, Nov. 29, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the LD Micro...

Read more

25 Nov

Intellipharmaceutics Submits New Drug Application for Rexista® (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, Nov. 25, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a New Drug Application (“NDA”) with the...

Read more

Page 1 of 612345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address